Journal
PHARMACOGENOMICS
Volume 19, Issue 10, Pages 861-871Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2018-0023
Keywords
nicotine replacement therapy; pharmacogenetics; precision medicine; smoking cessation
Categories
Funding
- National Institute on Drug Abuse [R01 DA038076, K08 DA030398]
- National Caner Institute [P30 CA091842-16S2]
- National Center for Research Resources [U54 MD010724, KL2 RR024994]
Ask authors/readers for more resources
Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available